You are here
Dr Christophe Badie
Theme 3 - Health impact of low dose non-ionising and ionising radiation
Public Health England
Christophe Badie leads the Cancer Genetics and Cytogenetics group in the research department of Biological Effects at Public Health England’s Centre for Radiation, Chemical and Environmental Hazards (CRCE). He obtained a BSc and a MSc in molecular biology and genetics; subsequently a PhD in radiation biology and pathology from the University of Paris XI, Orsay, France. He started his career as a post-doctoral research assistant first in Villejuif (Gustave Roussy Institute), then in London (Hammersmith hospital, Imperial College. In 2005 he moved to the National Radiological Protection Board (NRPB) as a group leader; NRPB became part of the Health Protection Agency and consequently, since 2013 part of Public Health England as CRCE.
Christophe Badie has 20 years of experience in research on radiation effects on health. His group is carrying out research into the fundamental mechanisms by which radiation causes cancer. There is particular focus on the identification and characterisation of genes, which influence individual susceptibility to radiation-induced cancer.
The group also conduct research on the chromosomal and molecular mechanisms that underlie leukaemia initiation and development and investigate specific genetic factors that influence haematopoietic cell radiosensitivity and cancer susceptibility. Studies of the early events in radiation carcinogenesis are important in the context of developing mechanistic models for cancer risk estimation. Within the group there is a significant pool of technical expertise in cytogenetics, molecular biology and cell biology. In the search of new transcriptional individual sensitivity and predictive markers, the group has developed sensitive assays for studying gene expression modifications using the state of the art technology (i.e. quantitative and now digital PCR). They recently demonstrated the linearity of the transcriptional dose-response and the inter-individual variability in response for low doses which have not been assessed until now.
He has significant involvement in European Union funded research through contributions to the DoReMi Network of Excellence, MELODI, OPERRA, RISK-IR and received support from the NIH in the US. He has a consistent publication record with over 40 peer-reviewed publications. He gives lectures for the MSc Radiation Biology at the Department of Oncology of the University of Oxford. He is a manuscript reviewer for several relevant international journals as well as UK and international funding bodies